Sun Pharma’s Strategic Pivot: U.S. Manufacturing Expansion on the Horizon

Sun Pharmaceutical Industries Ltd, India's leading pharmaceutical company, has signaled openness to expanding its manufacturing footprint in the United States. This strategic consideration comes in response to the Trump administration's 100% tariff on branded and patented medicines entering the U.S., a development that introduces uncertainty about the tariff's impact on Sun Pharma's generics and innovative medicines portfolio. Currently, Sun Pharma already maintains a significant manufacturing presence in the U.S.

 

In a recent analyst call, Richard Ascroft, CEO of Sun Pharma's North American business, emphasized that the company is continuously assessing its manufacturing operations and is open to considering localized production in the U.S. at an appropriate time. Executive Chairman Dilip Shanghvi reaffirmed the company’s commitment to launching new treatments in the U.S. market, including UNLOXCYT, an FDA-approved therapy for advanced skin cancer, and plans to file other specialty drugs in the upcoming fiscal year.

 

Notable updates:

This proactive stance indicates Sun Pharma’s adaptive strategy to sustain growth and competitiveness amid evolving regulatory and trade environments.

 

Sources: Reuters, Economic Times, Sun Pharma official media releases.